NHIA Submits Comments on Ig LCD
NHIA submitted comments pointing out the advantages of home-based administration of subcutaneous Ig (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIPD).
STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).
On April 19, 2022, Baxter announced a supply disruption of the ExactaMix valve sets (ExactaMix 1200 Valve Set H938792 and ExactaMix 2400 Valve Set H938724) due to raw material constraints that are impacting production volumes. As a result, healthcare providers and institutions are driven to consider conservation measures when compounding using the ExactaMix Automated Compounder.
The nature of this supply disruption is of grave concern, limiting the ability to safely prepare parenteral nutrition and other intravenous sterile products compounded using the ExactaMix device. Typical strategies for conservation may not easily translate to this supply disruption. NHIA has collaborated with the the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Society for Health System Pharmacists (ASHP) and the Institute for Safe Medication Practices (ISMP) to provide considerations for potential approaches to managing this supply disruption.
Download the considerations document (pdf)
Important Notes:
NHIA submitted comments pointing out the advantages of home-based administration of subcutaneous Ig (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIPD).
NHIA submitted comments on a CMS proposed rule (CMS-1770-P) that would affect Medicare payments and coverage of COVID-19 vaccines and monoclonal antibodies (mAbs) and coding and billing requirements related to the use of single dose containers and drug waste.
As part of a strategic focus on promoting health equity, The National Home Infusion Foundation (NHIF) recently adopted standardized categories for race and ethnicity data collection and is encouraging all providers to include voluntary questions to capture this data. NHIF will utilize this data throughout its projects to evaluate equitable access to infusion treatments in alternate sites.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |